Business Insider2d
Positive Buy Rating for Neurogene Driven by Promising Low-Dose NGN-401 Results and Proactive Safety Measures
William Blair analyst Sami Corwin has reiterated their bullish stance on NGNE stock, giving a Buy rating on November 12. Don't Miss our Black Friday Offers: Discover the latest stocks recommended by ...
Neurogene Stock Tanks After Adverse Event In Early-Stage Rett Syndrome Gene Therapy Trial
Neurogene reports interim Phase 1/2 trial results for NGN-401 gene therapy in treating pediatric Rett syndrome, showing ...
Nasdaq6d
Neurogene Stock Plummets 44%: Is All Hope Lost for This Biotech?"
Neurogene (NASDAQ: NGNE) stock just took a sharp dive, plummeting 44% in a single day. Bad news on Monday caused the pharmaceutical company’s shares to drop massively in after-hours trading ...
ENDPOINTS NEWS8d
Neu­ro­gene's stock falls in post-mar­ket trad­ing af­ter ear­ly da­ta in Rett syn­drome
Neurogene's stock {$NGNE} fell 35% in post-market trading on Monday after a Rett syndrome patient who received a high dose of ...
Yahoo Finance5d
NGNE Mar 2025 50.000 call (NGNE250321C00050000)
There are no important events for this country at this time. Select "All" to see top events in other countries or view all events.
Business Wire1mon
Neurogene to Present Interim Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases ...
Benzinga.com7d
Neurogene (NASDAQ:NGNE) Stock, Option Chain
Option chain shows key data for Neurogene's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for ...
news.stocktradersdaily2d
(NGNE) Investment Report
Check the time stamp on this data. Updated AI-Generated Signals for Neoleukin Therapeutics Inc. (NGNE) available here: NGNE.